Bimekizumab
Bimekizumab (Anti-Human IL17A/IL-17F Recombinant Antibody) is a humanised monoclonal antibody, can selectively neutralises IL-17A and IL-17F. Both of them are pro-osteogenic with respect to human periosteum-derived cell (hPDC) differentiation. Thus Bimekizumab blocks the inflammation-driven osteogenic differentiation[1].
Product Specifications
CAS Number
1418205-77-2
Product Name Alternative
Anti-Human IL17A/IL-17F Recombinant Antibody; CDP4940; UCB-4940
UNSPSC
12352203
Target
Interleukin Related
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/bimekizumab.html
Purity
99.00
Solubility
10 mM in DMSO
Smiles
[Bimekizumab]
Molecular Weight
(147.24 kDa)
References & Citations
[1]Shah M, et al. Dual neutralisation of IL-17F and IL-17A with bimekizumab blocks inflammation-driven osteogenic differentiation of human periosteal cells. RMD Open. 2020 Jul;6 (2) :e001306.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Launched
Isoform
IL-17
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC880988-500 1x 500 µL
CD54 (W-CAM-1; same as Wehi-CAM-1 or 1H4), CF488A conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
LC420737 20 µg
Neurokinin A Receptor (TACR2) (NM_001057) Human Over-expression Lysate
Sign In for Pricing
View Details 
